Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

6-Sulfonylbenzothiazolones as potential scaffolds for the design of 5-HT6 ligands.

Larchanche PE, Ultré V, Le Broc D, Ballandone C, Furman C, Dallemagne P, Melnyk P, Carato P.

Eur J Med Chem. 2015 Mar 6;92:807-17. doi: 10.1016/j.ejmech.2015.01.052. Epub 2015 Jan 26.

PMID:
25637882
2.

Design and synthesis of novel series of 5-HT6 receptor ligands having indole, a central aromatic core and 1-amino-4 methyl piperazine as a positive ionizable group.

Hayat F, Cho S, Rhim H, Indu Viswanath AN, Pae AN, Lee JY, Choo DJ, Choo HY.

Bioorg Med Chem. 2013 Sep 1;21(17):5573-82. doi: 10.1016/j.bmc.2013.05.051. Epub 2013 Jun 5.

PMID:
23810425
3.

8-Sulfonyl-substituted tetrahydro-1H-pyrido[4,3-b]indoles as 5-HT6 receptor antagonists.

Ivachtchenko AV, Mitkin OD, Tkachenko SE, Okun IM, Kysil VM.

Eur J Med Chem. 2010 Feb;45(2):782-9. doi: 10.1016/j.ejmech.2009.10.035. Epub 2009 Oct 31.

PMID:
19939513
4.

The computer-aided discovery of novel family of the 5-HT6 serotonin receptor ligands among derivatives of 4-benzyl-1,3,5-triazine.

Łażewska D, Kurczab R, Więcek M, Kamińska K, Satała G, Jastrzębska-Więsek M, Partyka A, Bojarski AJ, Wesołowska A, Kieć-Kononowicz K, Handzlik J.

Eur J Med Chem. 2017 Jul 28;135:117-124. doi: 10.1016/j.ejmech.2017.04.033. Epub 2017 Apr 13.

PMID:
28441580
5.

New 1-arylindoles based serotonin 5-HT7 antagonists. Synthesis and binding evaluation studies.

Sagnes C, Fournet G, Satala G, Bojarski AJ, Joseph B.

Eur J Med Chem. 2014 Mar 21;75:159-68. doi: 10.1016/j.ejmech.2014.01.055. Epub 2014 Jan 28.

PMID:
24531229
6.

Synthesis and biological evaluation of benzoisothiazole derivatives possessing N,N-dimethylformimidamide group as 5-HT₆ receptor antagonists.

Yoo E, Hayat F, Rhim H, Park Choo HY.

Bioorg Med Chem. 2012 Apr 15;20(8):2707-12. doi: 10.1016/j.bmc.2012.02.020. Epub 2012 Feb 16.

PMID:
22405919
7.
8.

Discovery of aryl-biphenyl-2-ylmethylpiperazines as novel scaffolds for 5-HT(7) ligands and role of the aromatic substituents in binding to the target receptor.

Kim Y, Kim J, Tae J, Roth BL, Rhim H, Keum G, Nam G, Choo H.

Bioorg Med Chem. 2013 May 1;21(9):2568-76. doi: 10.1016/j.bmc.2013.02.038. Epub 2013 Mar 6.

PMID:
23541835
9.

N1-(Benzenesulfonyl)tryptamines as novel 5-HT6 antagonists.

Tsai Y, Dukat M, Slassi A, MacLean N, Demchyshyn L, Savage JE, Roth BL, Hufesein S, Lee M, Glennon RA.

Bioorg Med Chem Lett. 2000 Oct 16;10(20):2295-9.

PMID:
11055342
10.

Synthesis and computer-aided SAR studies for derivatives of phenoxyalkyl-1,3,5-triazine as the new potent ligands for serotonin receptors 5-HT6.

Ali W, Więcek M, Łażewska D, Kurczab R, Jastrzębska-Więsek M, Satała G, Kucwaj-Brysz K, Lubelska A, Głuch-Lutwin M, Mordyl B, Siwek A, Nasim MJ, Partyka A, Sudoł S, Latacz G, Wesołowska A, Kieć-Kononowicz K, Handzlik J.

Eur J Med Chem. 2019 Sep 15;178:740-751. doi: 10.1016/j.ejmech.2019.06.022. Epub 2019 Jun 10.

PMID:
31229876
11.

Optimization of N'-(arylsulfonyl)pyrazoline-1-carboxamidines by exploiting a novel interaction site in the 5-HT6 antagonistic binding pocket.

van Loevezijn A, Venhorst J, Iwema Bakker WI, Lange JHM, de Looff W, Henzen R, de Vries J, van de Woestijne RP, den Hartog AP, Verhoog S, van der Neut MAW, de Bruin NMWJ, Kruse CG.

Bioorg Med Chem Lett. 2016 Mar 15;26(6):1605-1611. doi: 10.1016/j.bmcl.2016.02.001. Epub 2016 Feb 2.

PMID:
26876931
12.

5-HT6 receptor antagonists as potential therapeutics for cognitive impairment.

Rossé G, Schaffhauser H.

Curr Top Med Chem. 2010;10(2):207-21. Review.

PMID:
20166958
13.

Novel 1-(azacyclyl)-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines as 5-HT6 agonists and antagonists.

Elokdah H, Li D, McFarlane G, Bernotas RC, Robichaud AJ, Magolda RL, Zhang GM, Smith D, Schechter LE.

Bioorg Med Chem. 2007 Sep 15;15(18):6208-26. Epub 2007 Jun 14.

PMID:
17624788
14.

Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.

Yahiaoui S, Hamidouche K, Ballandonne C, Davis A, de Oliveira Santos JS, Freret T, Boulouard M, Rochais C, Dallemagne P.

Eur J Med Chem. 2016 Oct 4;121:283-293. doi: 10.1016/j.ejmech.2016.05.048. Epub 2016 May 26.

PMID:
27266998
15.

Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation.

de la Fuente T, Martín-Fontecha M, Sallander J, Benhamú B, Campillo M, Medina RA, Pellissier LP, Claeysen S, Dumuis A, Pardo L, López-Rodríguez ML.

J Med Chem. 2010 Feb 11;53(3):1357-69. doi: 10.1021/jm901672k.

PMID:
20078106
16.

Serotonin receptors of type 6 (5-HT6): from neuroscience to clinical pharmacology.

Marazziti D, Baroni S, Borsini F, Picchetti M, Vatteroni E, Falaschi V, Catena-Dell'Osso M.

Curr Med Chem. 2013;20(3):371-7. Review.

PMID:
23157629
17.

A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists.

López-Rodríguez ML, Benhamú B, de la Fuente T, Sanz A, Pardo L, Campillo M.

J Med Chem. 2005 Jun 30;48(13):4216-9.

PMID:
15974573
18.

5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds.

Ivachtchenko AV, Ivanenkov YA, Skorenko AV.

Expert Opin Ther Pat. 2012 Oct;22(10):1123-68. Epub 2012 Sep 7. Review.

PMID:
22957857
19.

Synthesis and SAR of 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines as potent serotonin 5-HT6 receptor antagonists.

Ivachtchenko AV, Golovina ES, Kadieva MG, Kysil VM, Mitkin OD, Tkachenko SE, Okun I.

Bioorg Med Chem. 2011 Feb 15;19(4):1482-91. doi: 10.1016/j.bmc.2010.12.055. Epub 2011 Jan 5.

PMID:
21277782
20.

The multiobjective based design, synthesis and evaluation of the arylsulfonamide/amide derivatives of aryloxyethyl- and arylthioethyl- piperidines and pyrrolidines as a novel class of potent 5-HT₇ receptor antagonists.

Zajdel P, Kurczab R, Grychowska K, Satała G, Pawłowski M, Bojarski AJ.

Eur J Med Chem. 2012 Oct;56:348-60. doi: 10.1016/j.ejmech.2012.07.043. Epub 2012 Aug 4.

PMID:
22926225

Supplemental Content

Support Center